Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: Comprehensive network meta-analysis

BMJ (Online)

Volumn 347, Issue , 2013, Pages

  Navarese, ElianoP ^a   Tandjung, Kenneth ^b   Claessen, Bimmer ^c   Andreotti, Felicita ^d   Kowalewski, Mariusz ^a   Kandzari, DavidE ^e   Kereiakes, DeanJ ^f   Waksman, Ron ^g   Mauri, Laura ^h   Meredith, IanT ⁱ   Finn, AlokeV ^j   Kim, Hyo Soo ^k   Kubica, Jacek ^a   Suryapranata, Harry ^l   Aprami, Toni Mustahsani ^m   Pasquale, Giuseppe Di ⁿ   Birgelen, Clemensvon ^b,o   Kedhi, Elvin ^p  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b MEDISCH SPECTRUM TWENTE   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d CATHOLIC UNIVERSITY   (Italy)

^e PIEDMONT HEART INSTITUTE   (United States)

^f The Carl & Edyth Lindner Center for Research & Education   (United States)

^g WASHINGTON HOSPITAL CENTER   (United States)

^h HARVARD MEDICAL SCHOOL   (United States)

ⁱ MONASH MEDICAL CENTRE   (Australia)

^j EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k Seoul National University College of Medicine   (South Korea)

^l RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^m PADJADJARAN UNIVERSITY   (Indonesia)

ⁿ MAGGIORE HOSPITAL   (Italy)

^o UNIVERSITY OF TWENTE   (Netherlands)

^p ISALA HOSPITAL   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; PACLITAXEL; RAPAMYCIN; UMIROLIMUS; ZOTAROLIMUS;

ACUTE CORONARY SYNDROME; ARTICLE; BIODEGRADABILITY; CLINICAL PRACTICE; CORONARY ARTERY DISEASE; DEATH; DRUG ELUTING STENT; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HUMAN; META ANALYSIS; MULTICENTER STUDY (TOPIC); PATIENT SAFETY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVASCULARIZATION; STENT THROMBOSIS; SYSTEMATIC REVIEW; THERAPY EFFECT; TREATMENT OUTCOME;

ABSORBABLE IMPLANTS; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION; POLYMERS; POSTOPERATIVE COMPLICATIONS; SIROLIMUS; THROMBOSIS; TREATMENT OUTCOME;

EID: 84888249190     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.f6530     Document Type: Article

References (121)

1. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation 2007;115:1440-55.
2. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007;369:667-78.
3. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48:193-202.
4. Palmerini T, Biondi-Zoccai G, Della Riva D, Stettler C, Sangiorgi D, D'Ascenzo F, et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 2012;379:1393-402.
5. Bangalore S, Kumar S, Fusaro M, Amoroso N, Attubato MJ, Feit F, et al. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation 2012;125:2873-91.
6. Sabate M, Cequier A, Iniguez A, Serra A, Hernandez-Antolin R, Mainar V, et al. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet 2012;380:1482-90.
7. Windecker S, Serruys PW, Wandel S, Buszman P, Trznadel S, Linke A, et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet 2008;372:1163-73.
8. Christiansen EH, Jensen LO, Thayssen P, Tilsted HH, Krusell LR, Hansen KN, et al. Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial. Lancet 2013;381:661-9.
9. Smits PC, Hofma S, Togni M, Vazquez N, Valdes M, Voudris V, et al. Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial. Lancet 2013;381:651-60.
10. Natsuaki M, Kozuma K, Morimoto T, Kadota K, Muramatsu T, Nakagawa Y, et al. Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent: a randomized, controlled, noninferiority trial. J Am Coll Cardiol 2013;62:181-90.
11. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344-51.
12. Higgins JPT, Green D. Cochrane handbook for systematic reviews of interventions. Version 5.1.0. Cochrane Collaboration, 2011. www.cochrane- handbook.org.
13. Cooper NJ, Peters J, Lai MC, Juni P, Wandel S, Palmer S, et al. How valuable are multiple treatment comparison methods in evidence-based health-care evaluation? Value Health 2011;14:371-80.
14. Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Stat Med 2010;29:932-44.
15. Spiegelhalter D, Abrams K, Myles J. Bayesian approaches to clinical trials and health-care evaluation (Statistics in Practice). Wiley, 2004.
16. Kaiser C, Brunner-La Rocca HP, Buser PT, Bonetti PO, Osswald S, Linka A, et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitats Trial (BASKET). Lancet 2005;366:921-9.
17. Kaiser C, Galatius S, Erne P, Eberli F, Alber H, Rickli H, et al. Drug-eluting versus bare-metal stents in large coronary arteries. N Engl J Med 2010;363:2310-9.
18. Park HJ, Kim HY, Lee JM, Choi YS, Park CS, Kim DB, et al. Randomized comparison of the efficacy and safety of zotarolimus-eluting stents vs. sirolimus-eluting stents for percutaneous coronary intervention in chronic total occlusion - CAtholic Total Occlusion Study (CATOS) trial. Circ J 2012;76:868-75.
19. Moreno R, Garcia E, Teles R, Rumoroso JR, Carvalho HC, Goicolea FJ, et al. Randomized comparison of sirolimus-eluting and everolimus-eluting coronary stents in the treatment of total coronary occlusions: results from the chronic coronary occlusion treated by everolimus-eluting stent randomized trial. Circ Cardiovasc Interv 2013;6:21-8.
20. Kedhi E, Joesoef KS, McFadden E, Wassing J, van Mieghem C, Goedhart D, et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet 2010;375:201-9.
21. Smits PC, Kedhi E, Royaards KJ, Joesoef KS, Wassing J, Rademaker-Havinga TA, et al. 2-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice. COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTE stent in all-comers: a randomized open label trial). J Am Coll Cardiol 2011;58:11-8.
22. De Lezo J, Medina A, Pan M, Romero M, Delgado A, Segura J, et al. Drug-eluting stents for complex lesions: randomized rapamycin versus paclitaxel CORPAL study. J Am Coll Cardiol 2005;45:75A.
23. Wang L, Zhang D, Yang X, Ge Y, Wang H, Li W, et al. Comparison of safety and efficacy of Cypher® stent and Endeavor® stent in patients with acute ST elevation myocardial infarction (STEMI) undergoing emergency PCI. J Am Coll Cardiol 2011;58:B216.
24. Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, et al. A randomized comparison of sirolimus- versus paclitaxel-eluting stent implantation in patients with diabetes mellitus 2-year clinical outcomes of the DES-DIABETES trial. J Am Coll Cardiol 2009;53:812-3.
25. Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, et al. A randomized comparison of sirolimus- versus paclitaxel-eluting stent implantation in patients with diabetes mellitus: 4-year clinical outcomes of DES-DIABETES (drug-eluting stent in patients with DIABETES mellitus) trial. JACC Cardiovasc Interv 2011;4:310-6.
26. Maeng M, Jensen LO, Galloe AM, Thayssen P, Christiansen EH, Hansen KN, et al. Comparison of the sirolimus-eluting versus paclitaxel-eluting coronary stent in patients with diabetes mellitus: the diabetes and drug-eluting stent (DiabeDES) randomized angiography trial. Am J Cardiol 2009;103:345-9.
27. Kandzari DE, Leon MB, Popma JJ, Fitzgerald PJ, O'Shaughnessy C, Ball MW, et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol 2006;48:2440-7.
28. Kandzari DE, Mauri L, Popma JJ, Turco MA, Gurbel PA, Fitzgerald PJ, et al. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (a randomized controlled trial of the medtronic endeavor drug [abt-578] eluting coronary stent system versus the cypher sirolimus-eluting coronary stent system in de novo native coronary artery lesions). JACC Cardiovasc Interv 2011;4:543-50.
29. Leon MB, Mauri L, Popma JJ, Cutlip DE, Nikolsky E, O'Shaughnessy C, et al. A randomized comparison of the ENDEAVOR zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial. J Am Coll Cardiol 2010;55:543-54.
30. Kirtane AJ, Leon MB, Ball MW, Bajwa HS, Sketch MH,Jr, Coleman PS, et al. The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a Zotarolimus-eluting stent with a Paclitaxel-eluting stent. JACC Cardiovasc Interv 2013;6:325-33.
31. Kim WJ, Lee SW, Park SW, Kim YH, Yun SC, Lee JY, et al. Randomized comparison of everolimus-eluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with diabetes mellitus (ESSENCE-DIABETES): results from the ESSENCE-DIABETES trial. Circulation 2011;124:886-92.
32. Park KW, Chae IH, Lim DS, Han KR, Yang HM, Lee HY, et al. Everolimus-eluting versus sirolimus-eluting stents in patients undergoing percutaneous coronary intervention: the EXCELLENT (Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting) randomized trial. J Am Coll Cardiol 2011;58:1844-54.
33. Hong SJ, Kim MH, Cha KS, Park HS, Chae SC, Hur SH, et al. Comparison of three-year clinical outcomes between sirolimus-versus paclitaxel-eluting stents in diabetic patients: prospective randomized multicenter trial. Catheter Cardiovasc Interv 2010;76:924-33.
34. Dibra A, Kastrati A, Mehilli J, Pache J, Schuhlen H, von Beckerath N, et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005;353:663-70.
35. Mehilli J, Kastrati A, Byrne RA, Bruskina O, Iijima R, Schulz S, et al. Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease. J Am Coll Cardiol 2009;53:1760-8.
36. Mehilli J, Richardt G, Valgimigli M, Schulz S, Singh A, Abdel-Wahab M, et al. Zotarolimusversus Everolimus-eluting stents for unprotected left main coronary artery disease. J Am Coll Cardiol 2013;Aug 8. doi:S0735-1097(13)03074-X
37. Mehilli J, Dibra A, Kastrati A, Pache J, Dirschinger J, Schomig A, et al. Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. Eur Heart J 2006;27:260-6.
38. Byrne RA, Mehilli J, Iijima R, Schulz S, Pache J, Seyfarth M, et al. A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents. Eur Heart J 2009;30:923-31.
39. Byrne RA, Kastrati A, Tiroch K, Schulz S, Pache J, Pinieck S, et al. 2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor [corrected] drug-eluting stents. J Am Coll Cardiol 2010;55:2536-43.
40. Juwana YB, Suryapranata H, Ottervanger JP, De Luca G, van't Hof AW, Dambrink JH, et al. Comparison of rapamycin- and paclitaxel-eluting stents in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction. Am J Cardiol 2009;104:205-9.
41. Kamoi D, Ishii H, Takahashi H, Aoyama T, Toriyama T, Tanaka M, et al. Sirolimus- vs. paclitaxel-eluting stent to coronary intervention in dialysis patients. Int J Cardiol 2013;165:533-6.
42. Kim MH, Hong SJ, Cha KS, Park HS, Chae SC, Hur SH, et al. Effect of Paclitaxel-eluting versus sirolimus-eluting stents on coronary restenosis in Korean diabetic patients. J Interv Cardiol 2008;21:225-31.
43. Kang WC, Ahn T, Lee K, Han SH, Shin EK, Jeong MH, et al. Comparison of zotarolimus-eluting stents versus sirolimus-eluting stents versus paclitaxel-eluting stents for primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: results from the Korean Multicentre Endeavor (KOMER) acute myocardial infarction (AMI) trial. EuroIntervention 2011;7:936-43.
44. Serruys PW, Farooq V, Kalesan B, de Vries T, Buszman P, Linke A, et al. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial. JACC Cardiovasc Interv 2013;6:777-89.
45. Kim YH, Park SW, Lee SW, Park DW, Yun SC, Lee CW, et al. Sirolimus-eluting stent versus paclitaxel-eluting stent for patients with long coronary artery disease. Circulation 2006;114:2148-53.
46. Park DW, Kim YH, Song HG, Ahn JM, Kim WJ, Lee JY, et al. Comparison of everolimusand sirolimus-eluting stents in patients with long coronary artery lesions: a randomized LONG-DES-III (Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-III) Trial. JACC Cardiovasc Interv 2011;4:1096-103.
47. Ahn JM, Park DW, Kim YH, Song H, Cho YR, Kim WJ, et al. Comparison of resolute zotarolimus-eluting stents and sirolimus-eluting stents in patients with de novo long coronary artery lesions: a randomized LONG-DES IV trial. Circ Cardiovasc Interv 2012;5:633-40.
48. Briguori C, Airoldi F, Visconti G, Focaccio A, Caiazzo G, Golia B, et al. Novel approaches for preventing or limiting events in diabetic patients (Naples-diabetes) trial: a randomized comparison of 3 drug-eluting stents in diabetic patients. Circ Cardiovasc Interv 2011;4:121-9.
49. Chevalier B, Serruys PW, Silber S, Garcia E, Suryapranata H, Hauptmann K, et al. Randomised comparison of Nobori, biolimus A9-eluting coronary stent with a Taxus(R), paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the Nobori 1 trial. EuroIntervention 2007;2:426-34.
50. Chevalier B, Silber S, Park SJ, Garcia E, Schuler G, Suryapranata H, et al. Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberte paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial - phase 2. Circ Cardiovasc Interv 2009;2:188-95.
51. Kadota K, Muramatsu T, Iwabuchi M, Saito S, Hayashi Y, Ikari Y, et al. Randomized comparison of the Nobori biolimus A9-eluting stent with the sirolimus-eluting stent in patients with stenosis in native coronary arteries. Catheter Cardiovasc Interv 2012;80:789-96.
52. Kimura T, Muramatsu T, Iwabuchi M, Saito S, Hayashi Y, Ikari Y. Three year follow up of a randomized comparison of Nobori, biolimus A9 eluting stent(BES) with Cypher, sirolimus eluting stent(SES) for coronary revascularization in japanese population. J Am Coll Cardiol 2012 ;17S:B216.
53. Pan M, Suarez de Lezo J, Medina A, Romero M, Delgado A, Segura J, et al. Drug-eluting stents for the treatment of bifurcation lesions: a randomized comparison between paclitaxel and sirolimus stents. Am Heart J 2007;153:15-e1.7.
54. Di Lorenzo E, Sauro R, Varricchio A, Capasso M, Lanzillo T, Manganelli F, et al. Benefits of drug-eluting stents as compared to bare metal stent in ST-segment elevation myocardial infarction: four year results of the PaclitAxel or Sirolimus-eluting stent vs bare metal stent in primary angiOplasty (PASEO) randomized trial. Am Heart J 2009;158:e43-50.
55. Petronio AS, De Carlo M, Branchitta G, Papini B, Ciabatti N, Gistri R, et al. Randomized comparison of sirolimus and paclitaxel drug-eluting stents for long lesions in the left anterior descending artery: an intravascular ultrasound study. J Am Coll Cardiol 2007;49:539-46.
56. Van den Branden BJ, Teeuwen K, Koolen JJ, van der Schaaf RJ, Henriques JP, Tijssen JG, et al. Primary Stenting of Totally Occluded Native Coronary Arteries III (PRISON III): a randomised comparison of sirolimus-eluting stent implantation with zotarolimus-eluting stent implantation for the treatment of total coronary occlusions. EuroIntervention 2013;Apr 30. doi:20120819-01
57. Lee JH, Kim HS, Lee SW, Park JH, Choi SW, Jeong JO, et al. Prospective randomized comparison of sirolimus- versus paclitaxel-eluting stents for the treatment of acute ST-elevation myocardial infarction: pROSIT trial. Catheter Cardiovasc Interv 2008;72:25-32.
58. Kim HS, Lee JH, Lee SW, Kim YH, Park JH, Choi SW, et al. Long-term safety and efficacy of sirolimus- vs. paclitaxel-eluting stent implantation for acute ST-elevation myocardial infarction: 3-year follow-up of the PROSIT trial. Int J Cardiol 2011;147:253-7.
59. Camenzind E, Wijns W, Mauri L, Kurowski V, Parikh K, Gao R, et al. Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial. Lancet 2012;380:1396-405.
60. Xu B, Yang Y, Yuan Z, Du Z, Wong SC, Genereux P, et al. Zotarolimus- and paclitaxel-eluting stents in an all-comer population in China: the RESOLUTE China randomized controlled trial. JACC Cardiovasc Interv 2013;6:664-70.
61. Morice MC, Colombo A, Meier B, Serruys P, Tamburino C, Guagliumi G, et al. Sirolimusvs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA 2006;295:895-904.
62. Kimura T, Morimoto T, Natsuaki M, Shiomi H, Igarashi K, Kadota K, et al. Comparison of everolimus-eluting and sirolimus-eluting coronary stents: 1-year outcomes from the Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting stent Trial (RESET). Circulation 2012;126:1225-36.
63. Serruys PW, Silber S, Garg S, van Geuns RJ, Richardt G, Buszman PE, et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med 2010;363:136-46.
64. Silber S, Windecker S, Vranckx P, Serruys PW, RESOLUTE All Comers investigators. Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. Lancet 2011;377:1241-7.
65. Burzotta F, Trani C, Todaro D, Mariani L, Talarico GP, Tommasino A, et al. Prospective randomized comparison of sirolimus- or everolimus-eluting stent to treat bifurcated lesions by provisional approach. JACC Cardiovasc Interv 2011;4:327-35.
66. Separham A, Sohrabi B, Aslanabadi N, Ghaffari S. The twelve-month outcome of biolimus eluting stent with biodegradable polymer compared with an everolimus eluting stent with durable polymer. J Cardiovasc Thorac Res 2011;3:113-6.
67. Windecker S, Remondino A, Eberli FR, Juni P, Raber L, Wenaweser P, et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 2005;353:653-62.
68. Raber L, Wohlwend L, Wigger M, Togni M, Wandel S, Wenaweser P, et al. Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE trial. Circulation 2011;123:2819-28.
69. Galloe AM, Thuesen L, Kelbaek H, Thayssen P, Rasmussen K, Hansen PR, et al. Comparison of paclitaxel- and sirolimus-eluting stents in everyday clinical practice: the SORT OUT II randomized trial. JAMA 2008;299:409-16.
70. Rasmussen K, Maeng M, Kaltoft A, Thayssen P, Kelbaek H, Tilsted HH, et al. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial. Lancet 2010;375:1090-9.
71. Maeng M, Tilsted HH, Jensen LO, Kaltoft A, Kelbaek H, Abildgaard U, et al. 3-Year clinical outcomes in the randomized SORT OUT III superiority trial comparing zotarolimus- and sirolimus-eluting coronary stents. JACC Cardiovasc Interv 2012;5:812-8.
72. Jensen LO, Thayssen P, Hansen HS, Christiansen EH, Tilsted HH, Krusell LR, et al. Randomized comparison of everolimus-eluting and sirolimus-eluting stents in patients treated with percutaneous coronary intervention: the Scandinavian Organization for Randomized Trials with Clinical Outcome IV (SORT OUT IV). Circulation 2012;125:1246-55.
73. Jensen LO, Thayssen P, Christiansen EH, Tilsted HH, Maeng M, Hansen KN, et al. 2-year patient-related versus stent-related outcomes: the SORT OUT IV (Scandinavian Organization for Randomized Trials With Clinical Outcome IV) Trial. J Am Coll Cardiol 2012;60:1140-7.
74. Serruys PW, Ruygrok P, Neuzner J, Piek JJ, Seth A, Schofer JJ, et al. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial. EuroIntervention 2006;2:286-94.
75. Onuma Y, Miquel-Hebert K, Serruys PW, SPIRIT II Investigators. Five-year long-term clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery disease: the SPIRIT II trial. EuroIntervention 2013;8:1047-51.
76. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA 2008;299:1903-13.
77. Applegate RJ, Yaqub M, Hermiller JB, Sood P, Yu S, Doostzadeh J, et al. Long-term (three-year) safety and efficacy of everolimus-eluting stents compared to paclitaxel-eluting stents (from the SPIRIT III Trial). Am J Cardiol 2011;107:833-40.
78. Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 2010;362:1663-74.
79. Stone GW, Rizvi A, Sudhir K, Newman W, Applegate RJ, Cannon LA, et al. Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial. J Am Coll Cardiol 2011;58:19-25.
80. Grube E, Chevalier B, Guagliumi G, Smits PC, Stuteville M, Dorange C, et al. The SPIRIT V diabetic study: a randomized clinical evaluation of the XIENCE V everolimus-eluting stent vs the TAXUS Liberte paclitaxel-eluting stent in diabetic patients with de novo coronary artery lesions. Am Heart J 2012;163: 867,875.e1.
81. Goy JJ, Stauffer JC, Siegenthaler M, Benoit A, Seydoux C. A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology: the TAXi trial. J Am Coll Cardiol 2005;45:308-11.
82. Berger A, Stauffer JC, Seydoux C, Siegenthaler M, Benoit A, Goy JJ. Three-year follow-up of the first prospective randomized comparison between paclitaxel and sirolimus stents: the TAXi-LATE trial. Catheter Cardiovasc Interv 2007;70:163-6.
83. von Birgelen C, Basalus MW, Tandjung K, van Houwelingen KG, Stoel MG, Louwerenburg JH, et al. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial. J Am Coll Cardiol 2012;59:1350-61.
84. Tandjung K, Sen H, Lam MK, Basalus MW, Louwerenburg JH, Stoel MG, et al. Clinical outcome following stringent discontinuation of dual antiplatelet therapy after 12 months in real-world patients treated with second-generation zotarolimus-eluting resolute and everolimus-eluting Xience V stents: 2-year follow-up of the randomized TWENTE trial. J Am Coll Cardiol 2013; Jun;61:2406-16.
85. Hofma SH, Brouwer J, Velders MA, van't Hof AW, Smits PC, Quere M, et al. Second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction. 1-year results of the randomized XAMI (XienceV Stent vs. Cypher Stent in Primary PCI for Acute Myocardial Infarction) trial. J Am Coll Cardiol 2012;60:381-7.
86. Park DW, Kim YH, Yun SC, Kang SJ, Lee SW, Lee CW, et al. Comparison of zotarolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for coronary revascularization: the ZEST (comparison of the efficacy and safety of zotarolimus-eluting stent with sirolimus-eluting and paclitaxel-eluting stent for coronary lesions) randomized trial. J Am Coll Cardiol 2010;56:1187-95.
87. Lee CW, Park DW, Lee SH, Kim YH, Hong MK, Kim JJ, et al. Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction. Am J Cardiol 2009;104:1370-6.
88. Zhang Q, Zhang RY, Zhang JS, Hu J, Yang ZK, Ni J, et al. One-year clinical outcomes of Chinese sirolimus-eluting stent in the treatment of unselected patients with coronary artery disease. Chin Med J (Engl) 2006;119:165-8.
89. Kereiakes DJ, Cannon LA, Feldman RL, Popma JJ, Magorien R, Whitbourn R, et al. Clinical and angiographic outcomes after treatment of de novo coronary stenoses with a novel platinum chromium thin-strut stent: primary results of the PERSEUS (Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System) trial. J Am Coll Cardiol 2010;56:264-71.
90. Kim HS, Park SJ, Park DW, Park SW, Cheong SS, Lee SG, et al. Comparison of the efficacy and safety of paclitaxel-eluting coroflex please stents and paclitaxel-eluting stents in patients with coronary artery disease: a randomized PIPA trial. Catheter Cardiovasc Interv 2012;1;80:799-806.
91. Stone GW, Teirstein PS, Meredith IT, Farah B, Dubois CL, Feldman RL, et al. A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery Lesions) trial. J Am Coll Cardiol 2011;57:1700-8.
92. Massberg S, Byrne RA, Kastrati A, Schulz S, Pache J, Hausleiter J, et al. Polymer-free sirolimus- and probucol-eluting versus new generation zotarolimus-eluting stents in coronary artery disease: the Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol-Eluting versus Zotarolimus-eluting Stents (ISAR-TEST 5) trial. Circulation 2011;124:624-32.
93. Ormiston JA, Abizaid A, Spertus J, Fajadet J, Mauri L, Schofer J, et al. Six-month results of the NEVO Res-Elution I (NEVO RES-I) trial: a randomized, multicenter comparison of the NEVO sirolimus-eluting coronary stent with the TAXUS Liberte paclitaxel-eluting stent in de novo native coronary artery lesions. Circ Cardiovasc Interv 2010;3:556-64.
94. Chevalier B, Di Mario C, Neumann FJ, Ribichini F, Urban P, Popma JJ, et al. A randomized, controlled, multicenter trial to evaluate the safety and efficacy of zotarolimus- versus paclitaxel-eluting stents in de novo occlusive lesions in coronary arteries The ZoMaxx I trial. JACC Cardiovasc Interv 2008;1:524-32.
95. Desch S, Schloma D, Mobius-Winkler S, Erbs S, Gielen S, Linke A, et al. Randomized comparison of a polymer-free sirolimus-eluting stent versus a polymer-based paclitaxel-eluting stent in patients with diabetes mellitus: the LIPSIA Yukon trial. JACC Cardiovasc Interv 2011;4:452-9.
96. Haude M, Erbel R, Erne P, Verheye S, Degen H, Bose D, et al. Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. Lancet 2013;381:836-44.
97. Waksman R, Barbash IM, Dvir D, Torguson R, Ben-Dor I, Maluenda G, et al. Safety and efficacy of the XIENCE V everolimus-eluting stent compared to first-generation drug-eluting stents in contemporary clinical practice. Am J Cardiol 2012;109:1288-94.
98. Ng VG, Lansky AJ, Hermiller JB, Farhat N, Applegate RJ, Yaqub M, et al. Three-year results of safety and efficacy of the everolimus-eluting coronary stent in women (from the SPIRIT III randomized clinical trial). Am J Cardiol 2011;107:841-8.
99. Kereiakes DJ, Cutlip DE, Applegate RJ, Wang J, Yaqub M, Sood P, et al. Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System). J Am Coll Cardiol 2010;56:2084-9.
100. Otake H, Ako J, Yamasaki M, Tsujino I, Shimohama T, Hasegawa T, et al. Comparison of everolimus- versus paclitaxel-eluting stents implanted in patients with diabetes mellitus as evaluated by three-dimensional intravascular ultrasound analysis. Am J Cardiol 2010;106:492-7.
101. Tada T, Byrne RA, Cassese S, King L, Schulz S, Mehilli J, et al. Comparative efficacy of 2 zotarolimus-eluting stent generations: resolute versus endeavor stents in patients with coronary artery disease. Am Heart J 2013;165:80-6.
102. Song YB, Hahn JY, Choi SH, Choi JH, Lee SH, Jeong MH, et al. Sirolimus- versus paclitaxel-eluting stents for the treatment of coronary bifurcations results: from the COBIS (Coronary Bifurcation Stenting) Registry. J Am Coll Cardiol 2010;55:1743-50.
103. Jensen LO, Maeng M, Thayssen P, Villadsen A, Krusell L, Botker HE, et al. Late lumen loss and intima hyperplasia after sirolimus-eluting and zotarolimus-eluting stent implantation in diabetic patients: the diabetes and drug-eluting stent (DiabeDES III) angiography and intravascular ultrasound trial. EuroIntervention 2011;7:323-31.
104. Mehilli J, Byrne RA, Wieczorek A, Iijima R, Schulz S, Bruskina O, et al. Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis. Eur Heart J 2008;29:1975-82.
105. Tomai F, Reimers B, De Luca L, Galassi AR, Gaspardone A, Ghini AS, et al. Head-to-head comparison of sirolimus- and paclitaxel-eluting stent in the same diabetic patient with multiple coronary artery lesions: a prospective, randomized, multicenter study. Diabetes Care 2008;31:15-9.
106. Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005;331:897-900.
107. Stefanini GG, Byrne RA, Serruys PW, de Waha A, Meier B, Massberg S, et al. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. Eur Heart J 2012;33:1214-22.
108. Navarese EP, Castriota F, Sangiorgi GM, Cremonesi A. From the abluminal biodegradable polymer stent to the polymer free stent. Clinical evidence. Minerva Cardioangiol 2013;61:243-54.
109. Kolandaivelu K, Swaminathan R, Gibson WJ, Kolachalama VB, Nguyen-Ehrenreich KL, Giddings VL, et al. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation 2011;123:1400-9.
110. Basalus MW, Ankone MJ, van Houwelingen GK, de Man FH, von Birgelen C. Coating irregularities of durable polymer-based drug-eluting stents as assessed by scanning electron microscopy. EuroIntervention 2009;5:157-65.
111. Basalus MWZ, Tandjung K, Sen H, van Apeldoorn AA, Grijpma DW, von Birgelen C. Recent insights from scanning electron microscopic assessment of durable polymer-coated drug-eluting stents. Interventional Cardiology 2012;6:661-674.
112. Applegate R, Hermiller J, Williams J, Gordon P, Doostzadeh J, Cao S, et al. Evaluation of the effects of everolimus-eluting and paclitaxel-eluting stents on target lesions with jailed side branches: 2-year results from the SPIRIT III randomized trial. Catheter Cardiovasc Interv 2010;76:644-51.
113. Joner M, Nakazawa G, Finn AV, Quee SC, Coleman L, Acampado E, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol 2008;52:333-42.
114. Nakatani S, Nishino M, Taniike M, Makino N, Kato H, Egami Y, et al. Initial findings of impact of strut width on stent coverage and apposition of sirolimus-eluting stents assessed by optical coherence tomography. Catheter Cardiovasc Interv 2013;81:776-81.
115. Vicenzi MN, Meislitzer T, Heitzinger B, Halaj M, Fleisher LA, Metzler H. Coronary artery stenting and non-cardiac surgery-a prospective outcome study. Br J Anaesth 2006;96:686-93.
116. Kedhi E, Stone GW, Kereiakes DJ, Serruys PW, Parise H, Fahy M, et al. Stent thrombosis: insights on outcomes, predictors and impact of dual antiplatelet therapy interruption from the SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE trials. EuroIntervention 2012;8:599-606.
117. Kirtane AJ, Silber S, Neumann FJ, Serruys PW, Mauri L, Meredith IT, et al. The relation between short and long-term antiplatelet use and stent thrombosis following percutaneous coronary intervention with the Resolute zotarolimus-eluting stent. J Am Coll Cardiol 2013;61(10S):E1862.
118. Hausleiter J, Kastrati A, Mehilli J, Schuhlen H, Pache J, Dotzer F, et al. Impact of lesion complexity on the capacity of a trial to detect differences in stent performance: results from the ISAR-STEREO trial. Am Heart J 2003;146:882-6.
119. Navarese EP, Kubica J, Castriota F, Gibson CM, De Luca G, Buffon A, et al. Safety and efficacy of biodegradable vs. durable polymer drug-eluting stents: evidence from a meta-analysis of randomised trials. EuroIntervention 2011;7:985-94.
120. Nakazawa G, Finn AV, John MC, Kolodgie FD, Virmani R. The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents. Am J Cardiol 2007;100:36-44M.
121. Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS), European Association for Percutaneous Cardiovascular Interventions (EAPCI), Wijns W, Kolh P, Danchin N, Di Mario C, et al. Guidelines on myocardial revascularization. Eur Heart J 2010;31:2501-55.